CLINUVEL Pharmaceuticals Sees Record Growth in H1/FY25

CLINUVEL Pharmaceuticals Ltd has reported record-high results for the first half of the fiscal year 2025. The company achieved a significant 27.4% increase in earnings per share, now at AU$28.1 cents, surpassing market expectations. This growth is attributed to high revenue and efficient cost management. Meanwhile, CLINUVEL is investing in future development and improving liquidity.

The company is focusing on three clinical projects: vitiligo, ACTH, and VP. With hopes for SCENESSE approval by 2028, CLINUVEL targets advancements in the US market. The upcoming launch of the "PhotoCosmetics" line and CYACÊLLE Radiant in late 2025 is a strategic move to diversify its revenue streams.

Despite operational success, CLINUVEL seeks a new CEO. The company's low valuation, alongside product and competition risks, persists as a concern for investors.